[Myeloid growth factors. New indications with many questions].
Palmblad
J
J
Forskare vid MFR och högskolelektor, Södersjukhuset, Stockholm.
Samuelsson
J
J
Glimelius
B
B
Ljungman
P
P
Nilsson
P G
PG
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D006133:Growth Substances; D006801:Humans; D000078224:Lenograstim; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D006133:Growth Substances; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C082430:molgramostim; D000069585:Filgrastim